BRPI0906478A2 - anticorpo anti-nr10 e uso do mesmo - Google Patents
anticorpo anti-nr10 e uso do mesmoInfo
- Publication number
- BRPI0906478A2 BRPI0906478A2 BRPI0906478A BRPI0906478A BRPI0906478A2 BR PI0906478 A2 BRPI0906478 A2 BR PI0906478A2 BR PI0906478 A BRPI0906478 A BR PI0906478A BR PI0906478 A BRPI0906478 A BR PI0906478A BR PI0906478 A2 BRPI0906478 A2 BR PI0906478A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Liquid Crystal (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2008/072152 | 2008-12-05 | ||
| PCT/JP2008/072152 WO2009072604A1 (ja) | 2007-12-05 | 2008-12-05 | 抗nr10抗体、およびその利用 |
| JPPCT/JP2009/054941 | 2009-03-13 | ||
| PCT/JP2009/054941 WO2010064456A1 (ja) | 2008-12-05 | 2009-03-13 | 抗nr10抗体、およびその利用 |
| PCT/JP2009/070376 WO2010064697A1 (ja) | 2008-12-05 | 2009-12-04 | 抗nr10抗体、およびその利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0906478A2 true BRPI0906478A2 (pt) | 2015-11-24 |
| BRPI0906478B1 BRPI0906478B1 (pt) | 2020-02-11 |
| BRPI0906478B8 BRPI0906478B8 (pt) | 2021-05-25 |
Family
ID=42233344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906478A BRPI0906478B8 (pt) | 2008-12-05 | 2009-12-04 | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2354161B1 (pt) |
| JP (1) | JP2010210772A (pt) |
| KR (1) | KR101271323B1 (pt) |
| BR (1) | BRPI0906478B8 (pt) |
| DK (1) | DK2354161T3 (pt) |
| ES (1) | ES2552690T3 (pt) |
| PL (1) | PL2354161T3 (pt) |
| PT (1) | PT2354161E (pt) |
| RU (1) | RU2487136C2 (pt) |
| WO (1) | WO2010064697A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| ES2544888T3 (es) | 2006-06-08 | 2015-09-04 | Chugai Seiyaku Kabushiki Kaisha | Prevención o remedio para enfermedades inflamatorias |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | 中外製藥股份有限公司 | Antibody constant region change body |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| CN105017420B (zh) * | 2012-02-17 | 2019-05-28 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
| TW201537175A (zh) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| FI3284480T3 (fi) * | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| PL234632B1 (pl) | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
| PL3749353T3 (pl) | 2018-02-09 | 2025-12-08 | Galderma Holding SA | Nemolizumab w leczeniu atopowego zapalenia skóry z przeczosami o nasileniu od umiarkowanego do ciężkiego |
| JP7549530B2 (ja) | 2018-05-21 | 2024-09-11 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
| US11236157B2 (en) | 2019-01-28 | 2022-02-01 | Galderma Holding SA | Treatment of skin lesions and pruritus in prurigo nodularis patients |
| SG11202110076PA (en) | 2019-04-02 | 2021-10-28 | Chugai Pharmaceutical Co Ltd | Method of introducing target-specific foreign gene |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
| TWI871349B (zh) * | 2020-09-01 | 2025-02-01 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物 |
| CA3189847A1 (en) * | 2020-09-01 | 2022-03-10 | Naoki Fukazawa | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
| WO2022113316A1 (ja) * | 2020-11-30 | 2022-06-02 | マルホ株式会社 | 線維化の進行抑制剤 |
| TW202304510A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商葛德瑪控股公司 | 結節性癢疹之治療 |
| EP4395657A1 (en) | 2021-08-30 | 2024-07-10 | Galderma Holding SA | Treatments for atopic dermatitis |
| WO2023120561A1 (ja) | 2021-12-22 | 2023-06-29 | 中外製薬株式会社 | 生物活性が低下した抗体バリアント |
| AU2023332656A1 (en) | 2022-09-02 | 2025-04-03 | Chugai Seiyaku Kabushiki Kaisha | Treatments for prurigo nodularis |
| WO2026115508A1 (en) | 2024-11-29 | 2026-06-04 | Chugai Seiyaku Kabushiki Kaisha | Treatment of chronic pruritus with unknown origin |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| RU2151612C1 (ru) * | 1992-12-01 | 2000-06-27 | Протеин Дизайн Лэбс, Инк. | Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2233974T3 (es) * | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| CZ106299A3 (cs) | 1996-09-26 | 1999-08-11 | Chugai Seiyaku Kabushiki Kaisha | Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| DK1188830T3 (da) | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| RU2490276C2 (ru) | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
| DE602004028347D1 (de) * | 2003-03-24 | 2010-09-09 | Zymogenetics Inc | Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung |
| CA2548185A1 (en) | 2003-12-03 | 2005-06-16 | Chugai Seiyaku Kabushiki Kaisha | Expression systems using mammalian .beta.-actin promoter |
| RU2481356C2 (ru) * | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| PE20061323A1 (es) * | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| ES2544888T3 (es) * | 2006-06-08 | 2015-09-04 | Chugai Seiyaku Kabushiki Kaisha | Prevención o remedio para enfermedades inflamatorias |
| WO2008100995A1 (en) * | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| HUE042172T2 (hu) * | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| ES2687808T3 (es) * | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| RU2505603C2 (ru) * | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| CA2708065C (en) * | 2007-12-05 | 2015-02-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| TWI548418B (zh) * | 2007-12-05 | 2016-09-11 | 中外製藥股份有限公司 | Anti-NR10 / IL-31RA antibody and its use |
-
2009
- 2009-03-09 JP JP2009054941A patent/JP2010210772A/ja active Pending
- 2009-12-04 PL PL09830463T patent/PL2354161T3/pl unknown
- 2009-12-04 WO PCT/JP2009/070376 patent/WO2010064697A1/ja not_active Ceased
- 2009-12-04 BR BRPI0906478A patent/BRPI0906478B8/pt active IP Right Grant
- 2009-12-04 KR KR1020107014700A patent/KR101271323B1/ko active Active
- 2009-12-04 PT PT98304637T patent/PT2354161E/pt unknown
- 2009-12-04 EP EP09830463.7A patent/EP2354161B1/en active Active
- 2009-12-04 ES ES09830463.7T patent/ES2552690T3/es active Active
- 2009-12-04 EP EP15172595.9A patent/EP2949672A1/en not_active Withdrawn
- 2009-12-04 DK DK09830463.7T patent/DK2354161T3/en active
- 2009-12-04 RU RU2010126078/10A patent/RU2487136C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| KR101271323B1 (ko) | 2013-06-04 |
| BRPI0906478B1 (pt) | 2020-02-11 |
| DK2354161T3 (en) | 2015-09-14 |
| JP2010210772A (ja) | 2010-09-24 |
| KR20100091245A (ko) | 2010-08-18 |
| ES2552690T3 (es) | 2015-12-01 |
| EP2354161A4 (en) | 2013-01-02 |
| EP2354161B1 (en) | 2015-08-12 |
| WO2010064697A1 (ja) | 2010-06-10 |
| PT2354161E (pt) | 2015-10-22 |
| EP2354161A1 (en) | 2011-08-10 |
| RU2010126078A (ru) | 2013-01-10 |
| RU2487136C2 (ru) | 2013-07-10 |
| EP2949672A1 (en) | 2015-12-02 |
| PL2354161T3 (pl) | 2016-01-29 |
| BRPI0906478B8 (pt) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0821110A2 (pt) | Anticorpo anti nr-10 e uso do mesmo | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI0821668A2 (pt) | Uso | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| DOP2010000260A (es) | Derivado heterociclico fusionado y su uso | |
| DK2234600T3 (da) | Antistofformulering | |
| BRPI1007494A2 (pt) | composto e uso do mesmo | |
| DK3072906T3 (da) | Antistofformulering | |
| EP2358392A4 (en) | ANTIBODY FORMULATION | |
| HUE038501T2 (hu) | Antitest készítmények | |
| BRPI0922708A2 (pt) | peptídeos mini-hepcidina e métodos de uso do mesmo | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| BRPI0924535A2 (pt) | Anticorpo de duplo direcionamento de nova forma, e uso do mesmmo | |
| SMT201500218B (it) | Composti aril-fenil-solfonammido-cicloalchile e loro uso | |
| PL2358756T3 (pl) | Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9 | |
| IL213116B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan | |
| DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| DK2349430T3 (da) | KATETERISERINGANORDNING og -kit | |
| BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
| EP2367570A4 (en) | ANTIBODIES TO IL-6 AND THEIR USE | |
| PL3059246T3 (pl) | Zmodyfikowany region stały przeciwciała | |
| CR20130360A (es) | Compuesto heterocíclico y su uso | |
| BRPI0716327A2 (pt) | Composto de fenilpropionamida e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |